Fresenius SE & Co. KGaA · XETR:FRE
Fresenius SE & Co. KGaA — Non-Deal Roadshow (May 2023)
38 slides from Fresenius SE & Co. KGaA's roadshow presentation, May 10, 2023
Slide 1: Executing on #FutureFresenius: Strong Q1/23 for Operating Companies
Executing on #FutureFresenius: Strong Q1/23 for Operating Companies, structural simplification on track London, May 10, 2023
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive
Slide 3: Business update
1 Business update 2 Financial review Q1/23 3 #FutureFresenius
Slide 4: #FutureFresenius – steady momentum
#FutureFresenius moving forward: Strong Q1 for Operating Companies, simplification on track Kabi and Helios accelerating performance with strong Q1 Structural productivity savings ramping up and showing impact Enhanced transparency on Kabi; CMD May 25 FMC deconsolidation moving ahead rapidly; EGM
Slide 5: Q1/23 – Good momentum at Kabi and Helios; outlook confirmed
Q1/23 – Good momentum at Kabi and Helios; earnings hit by Investment Companies; outlook confirmed Good growth momentum in all segments Revenues €10.2 bn (+5%) Operating Companies at upper end of growth band Operating Companies EBIT broadly flat, Investment Companies EBIT dilutive EBIT incl
Slide 6: Strong Q1/23 for Operating Companies – Kabi and Helios delivering
Strong Q1/23 for Operating Companies – Kabi and Helios delivering 14 17 9 11 EBIT (MARGIN) €289m 14.5% €311m 10.1% REVENUE €2.0bn +7% €3.1bn +5% (ORG. GROWTH) 4 7 3 5 KEY Strong organic revenue growth paced Healthy organic revenue growth driven MESSAGES by all three growth vectors Nutrition, by
Slide 7: FMC turnaround taking shape; EGM July 14
FMC turnaround taking shape; EGM July 14 Structural simplification on track EGM vote July 14 Enhanced reporting transparency Improving treatment volumes Focus on margin improvements FME25 starting to gain traction All growth rates in constant currency (cc) Before special items Roadshow L
Slide 8: Advancing patient care with innovative strengths in products and services
Advancing patient care with innovative strengths in products and services Recent highlights (sample) Vizient Innovative Technology Contract Pilot project for filtration concept and awarded for the Ivenix Infusion System reprocessing of narcotic gases FDA US agreed to waive KabiClear Line 2 in PU App
Slide 9: Financial review Q1/23
1 Business update 2 Financial review Q1/23 3 #FutureFresenius
Slide 10: Q1/23 – Good growth momentum
Q1/23 – Good growth momentum €10.2bn €908m €554m Healthy revenue growth of 5% in constant currency +5% -11/-10%1 -7% EBIT decline driven by expected annualization of inflationary effects such as cost increases for personnel, material, logistics, and energy REVENUE EBIT EBIT (INCL. FMC) (EX FMC)
Slide 11: Fresenius Kabi off to a good start to the year
Fresenius Kabi off to a good start to the year Q1/23 results QUARTERLY FINANCIALS MAIN DEVELOPMENTS Strong organic revenue growth in 15.9% all three growth vectors; 14.5% 2,000 EBIT Margin Biopharmaceuticals with ongoing strong growth momentum 14.3% 11.6% 13.5% Healthy growth in IV drugs & Reven
Slide 12: Fresenius Helios delivers solid Q1/23
Fresenius Helios delivers solid Q1/23 Q1/23 results QUARTERLY FINANCIALS MAIN DEVELOPMENTS 3,500 Healthy organic revenue growth 10.4% 10.4% 11.7% 10.1% mainly driven by Helios Spain including Latin America and Fertility EBIT Margin 3,000 EBIT margin well within structural margin band – 7.8% cont
Slide 13: Fresenius Vamed: Weak quarter, fixing underway
Fresenius Vamed: Weak quarter, fixing underway Q1/23 results QUARTERLY FINANCIALS MAIN DEVELOPMENTS 900 1.7% 2.0% Revenue growth driven by Technical 1.6% Services business and European Project business Revenue €m Weak EBIT negatively impacted by 500 -1.3% legacy project portfolio, business initi
Slide 14: Illustrative financial implications from change of FMC's legal form
Illustrative financial implications from change of Fresenius Medical Care’s legal form Incl. FMC Excl. FMC Current 2023 €m Q1/23 Q1/23 FMC fully consolidated Revenue 10,225 5,546 EGM July 14 EBIT 908 554 IFRS 5 application starts, likely leading to one-time non-cash P&L effect (special item); as per
Slide 15: Operating cash flow increased in Q1/23
Operating cash flow increased in Q1/23 Q1/23 Q1/22 €m Q1/23 Q1/22 Q1 structurally a weaker CF LTM LTM quarter with catch-up effects OCF 175 101 4,272 4,527 over the course of the year % OCF Margin 1.7% 1.0% 10.3% 11.8% Q1 OCF increased by 73% over weak prior year quarter Capex -352 -356 -1,773 -
Slide 16: Capital efficiency and returns to be improved over next quarters
Capital efficiency and returns to be improved over next quarters ROIC CCR NET DEBT/EBITDA1 10% 1.4 1.3 4.0 x 3.79 9% 1.2 1.1 1.1 3.65 3.61 8% 3.51 1.0 2 1.1 3.5 x 3.44 6.7 6.5 7% 5.9 0.8 0.7 6% 5.1 4.8 0.6 5% 3.0 x 4% 0.4 Q1/22: 5.6 LTM Q1/22: 1.0 Q1/22: 3.59 3% 0.2 2% 0.0 2.5 x 2019 2020 2021 2022
Slide 17: Ambitious cost savings program announced – execution well on track
Ambitious cost savings program announced – execution well on track Planned until 2025 Focus on 2023 Cost savings program is fully on Cost savings – EBIT view Expected Delivered track to deliver on 2023 targets Thereof FME ~€1,000m 2023 in Q1 and beyond ~€650m ~ €450m EBIT savings achieved – €500m
Slide 18: #FutureFresenius
1 Business update 2 Financial review Q1/23 3 #FutureFresenius
Slide 19: #FutureFresenius – Busy months, more to come
#FutureFresenius – Busy months, more to come Deliver 2023 and upgrade performance 2024+ Complete FMC deconsolidation Preparations fully on track Extraordinary General Meeting July 14 Kabi: Intensify focus and transparency Business-oriented disclosure available Upcoming CMD May 25 Continuousl
Slide 20: FMC deconsolidation on track for completion in Q3-4 2023
FMC deconsolidation on track for completion in Q3-4 2023 2023 Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Q1 Call Announcement Change of Legal Form Selection Procedure for New FMC Supervisory Board Legal Documentation Change of Invitation to FMC EGM legal form 14 July: FMC EGM Contestation Period
Slide 21: Fresenius Kabi Capital Market Day coming up in May
Fresenius Kabi Capital Market Day coming up in May Key topics London, UK #FutureFresenius – Fresenius Kabi’s contributions as operating company in advancing patient care May 25, 2023 Vision 2026 – Driving for margin enhancement and transformative growth “3+1” strategy delivery Performance ma
Slide 22: Attachments
= FRESENIUS Attachments
Slide 23: Outlook for FY/23
Outlook for FY/23 Fresenius Group Revenue growth (organic) EBIT (cc growth)1 including FMC: EBIT (cc growth) excluding FMC: Low-to-mid-single-digit growth Broadly flat-to-high-single Broadly flat-to-mid-single digit decline digit decline Operating Companies Investment Companies Low-to-mid-single-d
Slide 24: FY/23 – Other financial KPIs
FY/23 – Other financial KPIs One cent change in EUR/USD implies an annual effect of ~€140m on revenue, ~€15m on EBIT and Foreign exchange ~€4m on net income Higher interest rates leading to increased interest expenses of €700 to €750m for the group Profitability Interest expense depending on refinan
Slide 25: Illustrative financial implications from change of FMC's legal form
Illustrative financial implications from change of Fresenius Medical Care’s legal form 2023 July 14 Registration in H2/23 After conversion Current Extraordinary General Meeting Registration in commercial register At equity accounting • FMC fully • Application of IFRS 5 • Effective date AG conversion
Slide 26: Fresenius Kabi: Q1/23 Organic Revenue Growth by Product Group
Fresenius Kabi: Q1/23 Organic Revenue Growth by Product Group Δ YoY €m Q1/23 organic MedTech 378 9% Nutrition 602 8% Biopharma 71 57% Growth Vectors1 1,051 10% Pharma 940 3% (IV Drugs & Fluids) Total revenue 1,991 7% 1 consists of MedTech, Nutrition, Biopharma Roadshow London, May 10, 2023 © Freseni
Slide 27: Fresenius Kabi: Q1/23 EBIT(DA) development
Fresenius Kabi: Q1/23 EBIT(DA) development €m Q1/23 Δ YoY cc Total EBITDA 403 0% Margin 20.2% -120 bps Growth Vectors1 96 -17% Margin 9.2% -270 bps Pharma (IV Drugs & Fluids) 197 4% Margin 21.0% +60 bps Corporate -4 37% Total EBIT 289 -4% Margin 14.5% -140 bps All figures before special items Margin
Slide 28: Fresenius Helios: Q1/23 Key Financials
Fresenius Helios: Q1/23 Key Financials €m Q1/23 Δ YoY cc Total revenue 3,066 5%1 Thereof Helios Germany 1,828 3%1 Thereof Helios Spain 1,170 8%1 Thereof Helios Fertility 66 18%1 Total EBIT 311 2% Margin 10.1% -30 bps Thereof Helios Germany 155 1% Margin 8.5% -10 bps Thereof Helios Spain 157 4% Margi
Slide 29: Fresenius Helios: Key Metrics
Fresenius Helios: Key Metrics Q1/23 FY/22 Δ Helios Germany Hospitals 87 87 0% - Acute care hospitals 84 84 0% Beds 30,165 30,352 -1% - Acute care hospitals 29,599 29,786 -1% Admissions 1,433,728 5,508,158 - patients treated in hospital 287,317 1,079,776 - patients treated as outpatient 1,146,411 4,4
Slide 30: Fresenius Vamed: Q1/23 Key Financials
Fresenius Vamed: Q1/23 Key Financials €m Q1/23 Δ YoY cc Total revenue 583 13% Thereof organic revenue 13% Project business 147 36% Service business 436 7% Total EBIT1 -27 -- Order intake2 43 -- Order backlog2 3,580 -3%3 1 Before special items 2 Project business only 3 Versus December 31, 2022 Roadsh
Slide 31: Fresenius Group: Calculation of Noncontrolling Interests
Fresenius Group: Calculation of Noncontrolling Interests €m Q1/23 Q1/22 Earnings before tax and noncontrolling interests 738 881 Taxes -184 -200 Noncontrolling interests, thereof -165 -218 Fresenius Medical Care net income not attributable to Fresenius -106 -137 (FY/22: ~68%) Noncontrolling interest
Slide 32: Fresenius Group: Cash Flow
Fresenius Group: Cash Flow €m Q1/23 Q1/23 LTM Δ YoY LTM Margin Operating Cash Flow 175 4,272 10.3% 73% Capex (net) -352 -1,773 -4.3% 1% Free Cash Flow -177 2,499 6.0% 31% (before acquisitions and dividends) Acquisitions (net) -51 -789 Dividends -53 -887 Free Cash Flow -281 823 2.0% 30% (after acquis
Slide 33: Reconciliation adjusted Free Cash Flow for CCR
Fresenius Group: Reconciliation adjusted Free Cash Flow for CCR €m Q1/23 Q1/22 Operating Cash Flow 175 101 Capex (net) -352 -356 Free Cash Flow -177 -255 (before acquisitions and dividends) Special items (net income before minorities) +91 +82 Interests +170 +119 (before special items) Taxes +184 +20
Slide 34: Cash Flow development Q1/23
Cash Flow development Q1/23 Operating Cash Flow Capex (net) Free Cash Flow1 €m Q1/23 Q1/22 Q1/23 Q1/22 Q1/23 Q1/22 Q1/23 Q1/22 Q1/23 Q1/22 Q1/23 Q1/22 Margin Margin Margin Margin Margin Margin 21 133 1.1% 7.2% -83 -94 -4.2% -5.1% -62 39 -3.1% 2.1% 108 -136 3.5% -4.6% -95 -91 -3.1% -3.1% 13 -227 0.4%
Slide 35: Cash Flow development Q1/23 LTM
Cash Flow development Q1/23 LTM Operating Cash Flow Capex (net) Free Cash Flow1 €m Q1/23 Q1/22 Q1/23 Q1/22 Q1/23 Q1/22 Q1/23 Q1/22 Q1/23 Q1/22 Q1/23 Q1/22 LTM LTM Margin Margin LTM LTM Margin Margin LTM LTM Margin Margin 729 1,058 9.1% 14.5% -507 -506 -6.3% -6.9% 222 552 2.8% 7.6% 1,611 853 13.6% 7.
Slide 36: Revenue by Business Segment – FX, Acquisitions/Divestitures Effects Q1/23
Revenue by Business Segment – FX, Acquisitions/Divestitures Effects Q1/23 Growth at Currency Growth at Divesti- actual translation constant Organic Acquisi- tures/ €m Q1/23 Q1/22 rates effects rates growth tions Others Fresenius Kabi 1,991 1,847 8% 0% 8% 7% 2% -1% Fresenius Helios 3,066 2,931 5% 0%
Slide 37: Financial Calendar / Contact
Financial Calendar / Contact Financial Calendar Social Media 09 May 2023 Results Q1/23 Follow Fresenius Investor Relations & Sustainability on 17 May 2023 Annual General Meeting LinkedIn: 02 August 2023 Results Q2/23 02 November 2023 Results Q3/23 Please note that these dates could be subject to cha
Slide 38: = FRESENIUS
= FRESENIUS
Fresenius SE & Co. KGaA — Non-Deal Roadshow (May 2023) on 6ix